Progression of fibrosis in chronic hepatitis C. (Q44269259)

1 December 2017

Progression of fibrosis in chronic hepatitis C. (English)

1 reference

1 December 2017

1 reference

2

1 reference

1 December 2017

3

Harvey Alter

1 reference

1 December 2017

Marc G Ghany

1

1 reference

1 December 2017

Edward Doo

4

1 reference

1 December 2017

Farooq Khokar

5

1 reference

1 December 2017

Kittichai Promrat

6

1 reference

1 December 2017

David Herion

7

1 reference

1 December 2017

Yoon Park

8

1 reference

1 December 2017

T Jake Liang

9

1 reference

1 December 2017

Jay H Hoofnagle

10

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

1 December 2017

1 reference

1 December 2017

124

1 reference

1 December 2017

97-104

1 reference

1 December 2017

1

1 reference

Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study

1 December 2017

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1053/GAST.2003.50018

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1053/GAST.2003.50018

Histological grading and staging of chronic hepatitis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1053/GAST.2003.50018

Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1053/GAST.2003.50018

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1053/GAST.2003.50018

Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1053/GAST.2003.50018

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1053/GAST.2003.50018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1053/GAST.2003.50018

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1053/GAST.2003.50018

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1053/GAST.2003.50018

Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1053/GAST.2003.50018

The long-term pathological evolution of chronic hepatitis C.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1053/GAST.2003.50018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1053/GAST.2003.50018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1053/GAST.2003.50018

International collaborative study on the second EUROHEP HCV-RNA reference panel

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1053/GAST.2003.50018

Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C--a study of 527 patients at one establishment

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1053/GAST.2003.50018

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1053/GAST.2003.50018

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1053/GAST.2003.50018

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1053/GAST.2003.50018

Genotypic analysis of hepatitis C virus in American patients

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1053/GAST.2003.50018

Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1053/GAST.2003.50018

Identifiers

DOI

10.1053/GAST.2003.50018

1 reference

1 December 2017

1 reference